	US 12,138,303 B2
	Staphylococcus pseudintermedius virulence factor compositions
Stephen A. Kania, Powell, TN (US); David Bemis, Maryville, TN (US); and Mohamed A. Abouelkhair, Knoxville, TN (US)
Assigned to University of Tennessee Research Foundation, Knoxville, TN (US)
Filed by UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, Knoxville, TN (US)
Filed on Jul. 30, 2021, as Appl. No. 17/389,982.
Application 17/389,982 is a continuation of application No. 16/636,682, granted, now 11,141,473, previously published as PCT/US2018/046281, filed on Aug. 10, 2018.
Claims priority of provisional application 62/543,676, filed on Aug. 10, 2017.
Prior Publication US 2021/0379173 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/085 (2006.01); A61K 39/00 (2006.01); A61K 39/116 (2006.01); A61K 39/39 (2006.01); A61P 31/04 (2006.01); C07K 14/315 (2006.01)

CPC A61K 39/085 (2013.01) [A61P 31/04 (2018.01); A61K 39/00 (2013.01); A61K 39/116 (2013.01); A61K 39/39 (2013.01); A61K 2039/522 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/552 (2013.01); A61K 2039/575 (2013.01); C07K 14/315 (2013.01)]

2 Claims

1. A multivalent immunogenic composition comprising one or more recombinant attenuated Staphylococcus pseudintermedius immunoevasive virulence factors selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:12, or amino acid sequences having at least 95% identity to SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:8, and SEQ ID NO: 12.